The First Class of Biosimilars to Enter the US Market Will Generate $1.8 Billion by 2023
Decision Resources Group finds that sales of biosimilar versions of the granulocyte colony-stimulating factors (G-CSFs) filgrastim, which is currently pending FDA approval, and pegfilgrastim could reach $1.8 billion in the US by 2023. Medical oncologists and hematologist-oncologists surveyed in France and Germany indicated that they would prescribe future biosimilar G-CSFs, such as pegfilgrastim, to a significantly higher percentage of eligible patients compared with biosimilars of monoclonal antibodies (MAbs).
Other key findings from the Biosimilars Advisory Service report entitled Physician Perspectives on Granulocyte Colony-Stimulating Factors and Monoclonal Antibodies in Oncology:
• Rate of biosimilar uptake by oncologists: A greater proportion of surveyed oncologists indicated that they expect to start prescribing biosimilar G-CSFs within 6 months of availability, compared with biosimilar MAbs.
• Biosimilar preference: The majority of surveyed oncologists indicated that they have a preferred biosimilar filgrastim product and that preference is driven by which manufacturer they trust most.
• Influence of regulatory approval: The proportion of surveyed oncologists that indicated that regulatory approval would not allay all of their concerns about equivalence between a biosimilar and the reference brand was higher for MAbs than for G-CSFs.
Comments from Decision Resources Group Senior Director of Biosimilars Research Kate Keeping: "Filgrastim biosimilars have performed well in Europe, with sales exceeding the reference product in many countries. Now those biosimilars are on the verge of entering the US market where we expect US oncologists to swiftly adopt these tried and tested lower-cost alternatives to Amgen's Neupogen."
"Surveyed oncologists' responses indicated that they view the use of biosimilars differently in a therapeutic setting, compared with a supportive-care setting."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance